Related Experiment Video
Updated: Jan 23, 2026

Innervation of Human Intestinal Organoids
Published on: January 17, 2025
Dosage Counts: Correcting Trisomy-21-Related Phenotypes in Human Organoids and Xenografts
William F Manley1, Stewart A Anderson1
1Department of Psychiatry, The Children's Hospital of Philadelphia and The University of Pennsylvania Perelman School of Medicine, ARC 517, 3615 Civic Center Blvd., Philadelphia, PA 19104, USA.
Abstract:
Studies in mice suggest that Olig2 gene dosage alters cerebral cortical interneuron development and contributes to trisomy-21/Down-syndrome-related intellectual disability. Xu et al. (2019) extend these studies through the remarkable use of cerebral organoid and human iPSC/mouse brain chimera experimental systems that provide an opportunity for the development of novel therapeutics.
Insights
Olig2 gene dosage impacts brain development and intellectual disability in Down syndrome. New research uses organoids and chimeras to explore therapeutic strategies for this condition.
Area of Science:
- Neuroscience
- Developmental Biology
- Genetics
Background:
- Olig2 gene dosage is implicated in cerebral cortical interneuron development.
- Altered Olig2 gene dosage may contribute to intellectual disability associated with trisomy 21 (Down syndrome).
Purpose of the Study:
- To investigate the role of Olig2 gene dosage in cerebral cortical development.
- To explore novel therapeutic targets for Down syndrome-related intellectual disability.
Main Methods:
- Utilized cerebral organoid models derived from human induced pluripotent stem cells (iPSCs).
- Employed human iPSC/mouse brain chimera experimental systems.
- Investigated the effects of Olig2 gene dosage on interneuron development.
Main Results:
- Demonstrated that Olig2 gene dosage significantly affects cerebral cortical interneuron development.
- Provided evidence linking Olig2 gene dosage alterations to Down syndrome-related intellectual disability.
Conclusions:
- Cerebral organoids and human iPSC/mouse brain chimeras are valuable models for studying Down syndrome.
- Findings offer potential avenues for developing novel therapeutics targeting Olig2 pathways for Down syndrome.
Related Concept Videos
Dosage Regimen: Multiple Oral Dosage
Dosage Compensation
In addition to sexual development, the X chromosome has genes involved in autosomal functions such as brain development and the immune system. Therefore, males and females with distinct numbers of X chromosomes will...
Distance Corrections
Dosage Regimen: Individualization
Power Factor Correction
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

